Press release from Emotra AB (publ) Stockholm, 27 April 2022

Communiqué from the extraordinary general meeting of shareholders in Emotra AB (publ)

At the extraordinary general meeting of shareholders in EMOTRA AB (publ) ("Emotra" or "the Company") held today, 27 April 2022, in Stockholm, the following resolutions, among others, were passed.

Election of a board of directors and compensation to the board

The extraordinary meeting decided, in accordance with the board's proposal, that the board shall consist of four regular members and no deputy members.

In accordance with the board's proposal, Daniel Rudeklint was appointed as a new board member for the interim period until the next annual shareholder meeting, along with the present board members Claes Holmberg, Anders Blom and Ingela Hallberg.

Daniel Rudeklint

Born: 1981

Background: Daniel is employed as the CFO of Emotra AB since November 2021. Daniel has a business degree and several years' experience of auditing and internal auditing of companies and public authorities.

Education and professional experience: Luleå University of Technology, Master of sciences, business and economics, with a specialisation in management accounting and accounting.

CFO of Emotra AB since November 2021.

Certified public accountant at EY Sweden (previously Ernst & Young Sweden AB), 2007-2015. Internal auditor at Sida, the Swedish International Development Cooperation Agency, 2015-2021. Share ownership: -

The extraordinary meeting also decided, in accordance with the board's proposal, that the newly-appointed board member shall not receive any compensation, since he is already employed by the Company.

For further information, please contact: Claes Holmberg, Chairman of the Board Telephone: 0708 73 234 45 47

E-mail:claes@emotra.se

__________________________________________________________________________________ Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of neurological research mental health. The Company's methods/products, NeuraMetrix

TC and EDOR®, are unique, proprietary and patent-protected.

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden

Tel: +46 732-34 41 93,www.emotra.se

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Emotra AB published this content on 02 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 May 2022 11:46:07 UTC.